LENZ Therapeutics Reports Third Quarter 2026 Financial Results, Announces Strategic Consumer Marketing Focused Reorganization and CEO Succession
Q3 2026 VIZZ® product sales increased 50% over prior quarter, with strong momentum continuing into Q4 as consumer awareness broadens and telehealth adoption increases
Covered in this story
Analyst targets on Lenz Therapeutics Inc
- Bank of America: $4.6 → $7 by Aug 2027 · Neutral via seekingalpha.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $LENZ yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Lenz Therapeutics Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.